1Drucker D J. Development of glueagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes[ J ]. Curr Pharm Des ,2001,7 (14) : 1399-1412.
2Mu J, Woods J, Zhou Y P, et al. Chronic inhibition of dipetidy1 peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes[J]. Diabetes ,2006,55 ( 6 ) : 1695-1704.
3Baggio L L, Drucker D J. Clinical endocrinology and metabolism. Glucagon-like peptidc-1 and glucagon-like peptide-2 [ J ]. Best Pract Res Clin Endocrinol Metab, 2004,18 (4) : 531-554.
4Hoist J J, Deacon C F. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors [ J ]. Diabetologia, 2005,48 (4) :612-615.
5Degn K B,Juhl C B,Sturis J,et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide ( NN2211 ) markedly improves 24 h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes [ J ]. Diabetes, 2004,53 ( 5 ) : 1187-1194.
6Emoto M, Nishiawa Y, Maekawa K, et al. Homeostasis model assessment as a clinical index of insulin resistance in type 2 diabetic patients treated with sulfonylureas [ J ]. Diabetes Care, 1999,22 (5) :818-822.
7Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes ( LEAD-3 Mono) : randomised,52- week, phase Ⅲ, double-blind, parallel-treatment trial [ J ]. Lancet, 2009,373 ( 9662 ) :473- 481.
8Perfetti R,Zhou J, Doyle M E, et al. Glucagon-like peptide-1 induces cell proliferatin and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats[ J]. Endocrinology,2000,141 ( 12 ) :4600- 4605.
9Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes[ J]. Diabetes Care ,2007,30 ( 6 ) : 1608-1610.
10Michael N ,Ander F, Kjeld H, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with mefformin in type 2 diabetes [ J ]. Diabetes Care, 2009,32 ( 1 ) :84-90.
